In animal studies, ICOS was found to be necessary for optimal anti-tumor responses with anti-CTLA-4 [68] and ICOS was shown to mediate PI3K-signaling to increase T-bet expression in the setting of anti-CTLA-4 therapy [69]. Here, CTLA4 is linked to neoplasm.